Laventair Ellipta (previously Laventair)


umeclidinium bromide / vilanterol

This medicine is authorised for use in the European Union.


Laventair Ellipta is a medicine used to relieve the symptoms of chronic obstructive pulmonary disease (COPD) in adults. COPD is a long-term disease in which the airways and air sacs inside the lungs become damaged or blocked, leading to difficulty breathing. Laventair Ellipta is used for maintenance (regular) treatment.

Laventair Ellipta contains the active substances umeclidinium bromide and vilanterol.

This EPAR was last updated on 21/11/2022

Authorisation details

Product details
Laventair Ellipta (previously Laventair)
Agency product number
Active substance
  • umeclidinium bromide
  • vilanterol
International non-proprietary name (INN) or common name
  • umeclidinium bromide
  • vilanterol
Therapeutic area (MeSH)
Pulmonary Disease, Chronic Obstructive
Anatomical therapeutic chemical (ATC) code
Additional monitoringAdditional monitoring

This medicine is under additional monitoring, meaning that it is monitored even more intensively than other medicines. For more information, see Medicines under additional monitoring.

Publication details
Marketing-authorisation holder
GlaxoSmithKline (Ireland) Limited
Date of issue of marketing authorisation valid throughout the European Union
Contact address

12 Riverwalk
Citywest Business Campus
Dublin 24

Product information

09/11/2022 Laventair Ellipta (previously Laventair) - EMEA/H/C/003754 - PSUSA/00010264/202112

Other EU languages available icon This medicine’s product information is available in all official EU languages.
Select ‘available languages’ to access the language you need.


Product information documents contain:

You can find product information documents for centrally authorised human medicines on this website. For centrally authorised veterinary medicines authorised or updated from February 2022, see the Veterinary Medicines Information website.

Pharmacotherapeutic group

Drugs for obstructive airway diseases

Therapeutic indication

Laventair Ellipta is indicated as a maintenance bronchodilator treatment to relieve symptoms in adult patients with chronic obstructive pulmonary disease (COPD).

Assessment history

How useful was this page?

Add your rating
1 rating